{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:17Z","timestamp":1740126437837,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sigmund Freud Privatuniversit\u00e4t Wien"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In a\u00a0retrospective study, we analyzed the prevalence of subnormal prothrombin time (PT) values in 104\u00a0patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with clinicolaboratory features. Reduced PT values (&lt;\u202f70%) were found in 45\/104 (43%) patients. The median survival of patients with reduced PT values was significantly shorter than in patients with normal PT (19 vs. 49\u00a0months, <jats:italic>p<\/jats:italic>\u202f=\u20090.006). Patients with reduced PT had higher leukocyte counts, a\u00a0higher proportion of circulating blast cells, and lower platelet counts. In patients for whom clinical information was available, there was no difference in the incidence of bleeding complications between patients with or without reduced PT. Our results show a\u00a0high prevalence of plasmatic coagulation abnormalities in patients with CMML, which were associated with laboratory features of advanced disease. Moreover, subnormal PT values were identified as a\u00a0new prognostic marker. Reduced PT values do not seem to have a\u00a0clinical impact regarding bleeding complications.<\/jats:p>","DOI":"10.1007\/s10354-022-00969-4","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T07:05:17Z","timestamp":1665126317000},"page":"9-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia","Bedeutung einer gest\u00f6rten plasmatischen Gerinnung bei Patienten mit chronischer myelomonozyt\u00e4rer Leuk\u00e4mie"],"prefix":"10.1007","volume":"173","author":[{"given":"Christoph","family":"Weinfurtner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-7034","authenticated-orcid":false,"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"issue":"2","key":"969_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett\u00a0JM, Catovsky\u00a0D, Daniel\u00a0MT, et\u00a0al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189\u201399.","journal-title":"Br J Haematol"},{"issue":"7","key":"969_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman\u00a0JW, Harris\u00a0NL, Brunning\u00a0RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292\u2013302.","journal-title":"Blood"},{"issue":"5","key":"969_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman\u00a0JW, Thiele\u00a0J, Arber\u00a0DA, et\u00a0al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"20","key":"969_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"3","key":"969_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida\u00a0F, Kantarjian\u00a0HM, Smith\u00a0TL, et\u00a0al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a\u00a0retrospective analysis of 213\u00a0patients. Blood. 2002;99(3):840\u20139.","journal-title":"Blood"},{"issue":"7","key":"969_CR6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik\u00a0MM, Padron\u00a0E, LaBorde\u00a0RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504\u201310.","journal-title":"Leukemia"},{"issue":"19","key":"969_CR7","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Kosmider\u00a0O, Renneville\u00a0A, et\u00a0al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J\u00a0Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"10","key":"969_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena\u00a0C, Gall\u00ec\u00a0A, Such\u00a0E, et\u00a0al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"2","key":"969_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ejh.13647","volume":"107","author":"S Machherndl-Spandl","year":"2021","unstructured":"Machherndl-Spandl\u00a0S, J\u00e4ger\u00a0E, Barna\u00a0A, et al. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. Eur J Haematol. 2021;107(2):265\u201374.","journal-title":"Eur J Haematol"},{"issue":"9","key":"969_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","volume":"6","author":"P Fenaux","year":"1988","unstructured":"Fenaux\u00a0P, Beuscart\u00a0R, Lai\u00a0JL, et\u00a0al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107\u00a0cases. J\u00a0Clin Oncol. 1988;6(9):1417\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"969_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","volume":"100","author":"U Germing","year":"2002","unstructured":"Germing\u00a0U, Strupp\u00a0C, Aivado\u00a0M, et\u00a0al. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731\u20132. author reply 732\u2013733.","journal-title":"Blood"},{"issue":"11","key":"969_CR12","first-page":"766","volume":"4","author":"AM Storniolo","year":"1990","unstructured":"Storniolo\u00a0AM, Moloney\u00a0WC, Rosenthal\u00a0DS, et\u00a0al. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766\u201370.","journal-title":"Leukemia"},{"issue":"12","key":"969_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","volume":"38","author":"E Schuler","year":"2014","unstructured":"Schuler\u00a0E, Schroeder\u00a0M, Neukirchen\u00a0J, et\u00a0al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res. 2014;38(12):1413\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"969_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","volume":"64","author":"A Tefferi","year":"1989","unstructured":"Tefferi\u00a0A, Hoagland\u00a0HC, Therneau\u00a0TM, et\u00a0al. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc. 1989;64(10):1246\u201354.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"969_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","volume":"68","author":"A Worsley","year":"1988","unstructured":"Worsley\u00a0A, Oscier\u00a0DG, Stevens\u00a0J, et\u00a0al. Prognostic features of chronic myelomonocytic leukaemia: a\u00a0modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68(1):17\u201321.","journal-title":"Br J Haematol"},{"issue":"3","key":"969_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such\u00a0E, Cervera\u00a0J, Costa\u00a0D, et\u00a0al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375\u201383.","journal-title":"Haematologica"},{"issue":"15","key":"969_CR17","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such\u00a0E, Germing\u00a0U, Malcovati\u00a0L, et\u00a0al. Development and validation of a\u00a0prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315.","journal-title":"Blood"},{"issue":"12","key":"969_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie\u00a0EA, Itzykson\u00a0R, Lasho\u00a0TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a\u00a0Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111\u20135.","journal-title":"Am J Hematol"},{"issue":"6","key":"969_CR19","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","volume":"2","author":"R Itzykson","year":"2018","unstructured":"Itzykson\u00a0R, Fenaux\u00a0P, Bowen\u00a0D, et\u00a0al. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European leukemianet. Hemasphere. 2018;2(6):e150.","journal-title":"Hemasphere"},{"issue":"11","key":"969_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik\u00a0MM, Itzykson\u00a0R, Lasho\u00a0TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a\u00a0two-center study of 466\u00a0patients. Leukemia. 2014;28(11):2206\u201312.","journal-title":"Leukemia"},{"issue":"7","key":"969_CR21","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"Padron\u00a0E, Garcia-Manero\u00a0G, Patnaik\u00a0MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a\u00a0need for novel prognostication strategies. Blood Cancer\u00a0J. 2015;5(7):e333.","journal-title":"Blood Cancer J"},{"issue":"17\u201318","key":"969_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00508-019-1526-1","volume":"131","author":"K Geissler","year":"2019","unstructured":"Geissler\u00a0K, J\u00e4ger\u00a0E, Barna\u00a0A, et al. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): a\u00a0representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019;131(17\u201318):410\u20138.","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"969_CR23","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2013.100","volume":"27","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Solary\u00a0E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441\u201350.","journal-title":"Leukemia"},{"issue":"4","key":"969_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/ijlh.13212","volume":"42","author":"K Foucar","year":"2020","unstructured":"Foucar\u00a0K, Hsi\u00a0ED, Wang\u00a0SA, et\u00a0al. Concordance among hematopathologists in classifying blasts plus promonocytes: a bone marrow pathology group study. Int J Lab Hem. 2020;42(4):418\u201322.","journal-title":"Int J Lab Hem"},{"issue":"6","key":"969_CR25","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/1097-0142(197912)44:6<2249::AID-CNCR2820440637>3.0.CO;2-Z","volume":"44","author":"RD Gingrich","year":"1979","unstructured":"Gingrich\u00a0RD, Burns\u00a0CP. Disseminated coagulopathy in chronic myelomonocytic leukemia. Cancer. 1979;44(6):2249\u201353.","journal-title":"Cancer"},{"issue":"1","key":"969_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jlb.42.1.36","volume":"42","author":"E Karhum\u00e4ki","year":"1987","unstructured":"Karhum\u00e4ki\u00a0E, Saravo\u00a0L, Helin\u00a0H. Cells of the human myelomonocytic line RC-2A synthesize tissue factor-like procoagulant and urokinase-type plasminogen activator. J\u00a0Leukoc Biol. 1987;42(1):36\u201342.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"969_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2141.1987.tb06142.x","volume":"65","author":"P Fenaux","year":"1987","unstructured":"Fenaux\u00a0P, Jouet\u00a0JP, Zandecki\u00a0M, et\u00a0al. Chronic and subacute myelomonocytic leukaemia in the adult: a\u00a0report of 60\u00a0cases with special reference to prognostic factors. Br J Haematol. 1987;65(1):101\u20136.","journal-title":"Br J Haematol"},{"key":"969_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx187","author":"S Khozin","year":"2017","unstructured":"Khozin\u00a0S, Blumenthal\u00a0GM, Pazdur\u00a0R. Real-world Data for Clinical Evidence Generation in Oncology. Jnci: J Natl Cancer Inst. 2017; https:\/\/doi.org\/10.1093\/jnci\/djx187.","journal-title":"Jnci: J Natl Cancer Inst"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-022-00969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-022-00969-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-022-00969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T07:16:50Z","timestamp":1674631010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-022-00969-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":28,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s10354-022-00969-4","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"type":"print","value":"0043-5341"},{"type":"electronic","value":"1563-258X"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Weinfurtner and K.\u00a0Geissler declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}